Argentina vs Saudi Arabia: The number of people with susceptibility test result for rifampicin
Argentina
36.41
in 2021
Saudi Arabia
33.85
in 2021
Argentina rank
127th
Saudi Arabia rank
129th
The number of people with susceptibility test result for rifampicin over time
- Argentina
- Saudi Arabia
How they compare
Argentina currently reports 36.41 against 33.85 in Saudi Arabia, a difference of 2.56.
That makes Argentina's figure about 1.1 times Saudi Arabia's.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Saudi Arabia ahead.
Argentina ranks 127th and Saudi Arabia ranks 129th of 146 countries.
Saudi Arabia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Argentina | Saudi Arabia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 22.37 | 59.92 | 37.55 | Saudi Arabia |
| 2020s | 30.62 | 35.33 | 4.71 | Saudi Arabia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Argentina or Saudi Arabia?
- Argentina, at 36.41 against 33.85 in Saudi Arabia as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Argentina and Saudi Arabia?
- 2.56, with Argentina ahead.
- How many years of comparable data are there for Argentina and Saudi Arabia?
- 5 years are reported by both, from 2017 to 2021.
- How do Argentina and Saudi Arabia rank globally for the number of people with susceptibility test result for rifampicin?
- Argentina ranks 127th and Saudi Arabia ranks 129th of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.